Michael Juchum

Trigonal (-3) symmetry octahedral lanthanide(III) complexes of zwitterionic tripodal ligands: luminescence and magnetism

Tanya K. Ronson, R. Clérac, S. Brooker, 2016 .

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

S. Laufer, D. Rauh, Jonas Lategahn, 2017, Journal of medicinal chemistry.

Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant.

S. Laufer, G. Kelter, H. Fiebig, 2016, Angewandte Chemie.

Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.

M. Lämmerhofer, S. Laufer, Adrian Sievers-Engler, 2017, Journal of medicinal chemistry.

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.

S. Laufer, Michael Juchum, Marcel Günther, 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.

L. Zender, S. Laufer, W. Albrecht, 2021, European journal of medicinal chemistry.

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.

L. Zender, Stefan A. Laufer, W. Albrecht, 2022, European journal of medicinal chemistry.

From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).

L. Zender, S. Laufer, W. Albrecht, 2020, European journal of medicinal chemistry.

Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.

S. Laufer, W. Albrecht, Tatu Pantsar, 2020, European journal of medicinal chemistry.